scholarly journals Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera

2007 ◽  
Vol 122 (3) ◽  
pp. 279-287 ◽  
Author(s):  
Zeyu Xiong ◽  
Yan Yan ◽  
Enli Liu ◽  
Richard T. Silver ◽  
Srdan Verstovsek ◽  
...  
Keyword(s):  
Polycythemia Vera ◽  
Tumor Antigens ◽  
Immune Reactions ◽  
Humoral Immune

EFFET DE L'INOCULATION SUBSÉQUENTE DU VIRUS SV40 SUR LA TRANSPLANTATION DE CELLULES TRANSFORMÉES PAR CE VIRUS

1967 ◽  
Vol 13 (5) ◽  
pp. 543-549 ◽  
Author(s):  
R. Dubreuil ◽  
E. di Franco ◽  
V. Pavilanis ◽  
P. Marois
Keyword(s):  
Transformed Cells ◽  
Oncogenic Virus ◽  
Transplanted Tumors ◽  
Immune Reactions ◽  
Humoral Immune ◽  
Transplanted Tumor ◽  
Second Transplantation ◽  
Immunological Reactions ◽  
Virus Sv40

The inoculation of SV40 virus during the few days following the transplantation of SV40-transformed cells to adult hamsters inhibits the development of the transplanted tumors. The number and the size of the tumors are markedly reduced relative to those developing in control animals inoculated with medium 199.The animals that were resistant to the first transplantation, and those where the tumors were excised, showed an increased resistance to a second transplantation effected after an interval of 8 months.These results are interpreted as supporting the view that the transplantation of virus-transformed cells, and the development of the transplanted tumor, induce complex immunological reactions. The homologous oncogenic virus can be used to modify favorably the balance between cellular and humoral immune reactions conducive to the development of the tumor.

IMMUNOSUPPRESSIVE EFFECT OF BREDININ ON CELL-MEDIATED AND HUMORAL IMMUNE REACTIONS IN EXPERIMENTAL ANIMALS

1983 ◽  
Vol 35 (2) ◽  
pp. 144-149 ◽  
Author(s):  
KOJU KAMATA ◽  
MICHIHITO OKUBO ◽  
EIKO ISHIGAMORI ◽  
YOSHIHIKO MASAKI ◽  
HISANORI UCHIDA ◽  
...  
Keyword(s):  
Immunosuppressive Effect ◽  
Immune Reactions ◽  
Experimental Animals ◽  
Humoral Immune

Blood-borne human plasma cells in steady state are derived from mucosal immune responses

Blood ◽  
2009 ◽  
Vol 113 (11) ◽  
pp. 2461-2469 ◽  
Author(s):  
Henrik E. Mei ◽  
Taketoshi Yoshida ◽  
Wondossen Sime ◽  
Falk Hiepe ◽  
Kathi Thiele ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Steady State ◽  
Immune Responses ◽  
Plasma Cells ◽  
Immunoglobulin A ◽  
Low Frequency ◽  
Substantial Contribution ◽  
Immune Reactions ◽  
Humoral Immune ◽  
Humoral Immune Responses

AbstractProviding humoral immunity, antibody-secreting plasma cells and their immediate precursors, the plasmablasts, are generated in systemic and mucosal immune reactions. Despite their key role in maintaining immunity and immunopathology, little is known about their homeostasis. Here we show that plasmablasts and plasma cells are always detectable in human blood at low frequency in any unimmunized donor. In this steady state, 80% of plasmablasts and plasma cells express immunoglobulin A (IgA). Expression of a functional mucosal chemokine receptor, C-C motif receptor 10 (CCR10) and the adhesion molecule β7 integrin suggests that these cells come from mucosal immune reactions and can return to mucosal tissue. These blood-borne, CCR10+ plasmablasts also are attracted by CXCL12. Approximately 40% of plasma cells in human bone marrow are IgA+, nonmigratory, and express β7 integrin and CCR10, suggesting a substantial contribution of mucosal plasma cells to bone marrow resident, long-lived plasma cells. Six to 8 days after parenteral tetanus/diphtheria vaccination, intracellular IgG+ cells appear in blood, both CD62L+, β7 integrin−, dividing, vaccine-specific, migratory plasmablasts and nondividing, nonmigratory, CD62L− plasma cells of different specificities. Systemic vaccination does not impact on peripheral IgA+ plasmablast numbers, indicating that mucosal and systemic humoral immune responses are regulated independent of each other.

scholarly journals An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Antitumor Humoral Immune Reactions

2006 ◽  
Vol 177 (7) ◽  
pp. 4907-4916 ◽  
Author(s):  
Zeyu Xiong ◽  
Enli Liu ◽  
Yan Yan ◽  
Richard T. Silver ◽  
Fan Yang ◽  
...  
Keyword(s):  
Internal Ribosome Entry Site ◽  
Entry Site ◽  
Internal Ribosome Entry ◽  
Immune Reactions ◽  
Humoral Immune

Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 3004-3004 ◽  
Author(s):  
H. H. Soliman ◽  
S. Antonia ◽  
D. Sullivan ◽  
N. Vanahanian ◽  
C. Link
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Tumor Antigen ◽  
Tumor Antigens ◽  
Enzyme Inhibitor ◽  
Humoral Immune ◽  
T Cell Anergy ◽  
Solid Malignancies ◽  
Orally Bioavailable ◽  
200Mg Daily

3004 Background: The limited effect of cancer immunotherapy is due to the tumor's ability to induce host anergy towards its antigens. The enzyme indoleamine 2,3-dioxygenase (IDO) is thought to play a key role in anergy induction. IDO metabolizes tryptophan (trp) into immunosuppressive metabolites such as kynurenine (kyn). The oral IDO inhibitor, 1-methyl-D-tryptophan (1MT), was studied in preclinical models. The preclinical data support the activity of 1-MT in preventing T-cell anergy in TDLN, slowing growth of LLC mouse xenografts, and synergizing with chemotherapy in regression of autochthonous breast tumors in MMTV-Neu mice. This led to a phase I first-in-man trial using 1-MT in solid tumors. Methods: This is a phase I study treating adults with refractory solid malignancies. Patients are treated with up to 6 consecutive 28-day cycles starting at 200mg once daily. A 3+3 dose escalation to MTD is used. PK analysis, weekly labs, and CT scans every 2 cycles were done. Correlative studies include serum kyn/trp levels, T-reg cell quantification by flow, tumor IDO expression by IHC, and humoral immune response using a proprietary tumor antigen microarray. Results: Ten pts have recieved 1-MT at 200mg daily. Tumors treated included 1 esophageal, 1 peritoneal, 3 melanomas, 2 sarcomas, and 3 NSCLC. PK results show good bioavailability and a t1/2 of 2–4 hrs. Of the 7 evaluable pts, 4 had SD and 3 had PD. Attributable toxicities were 1 case of grade 1 fatigue and 2 cases of grade 2 hypophysitis. Both cases occurred in pts who received prior immunotherapies. Six new pts without prior immunotherapy were enrolled at the 200mg dose level. Five pts remain on treatment currently. Three pts had decreased T-reg cells after treatment with 1MT and 4 pts showed marked CRP increases. One pt had increased autoantibody titers against 3 tumor antigens compared to baseline. Conclusions: 1-MT appears to be an active, orally bioavailable, and reasonably well tolerated immunomodulator at 200mg daily. Development of hypophysitis in 2 patients indicates the drug can break tolerance resulting in autoimmunity. Enrollment to the trial continues. Future trials will combine 1-MT with other immunotherapies and chemotherapies for solid tumors. [Table: see text]

scholarly journals Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome

2015 ◽  
Vol 21 (16) ◽  
pp. 3619-3630 ◽  
Author(s):  
Debraj GuhaThakurta ◽  
Nadeem A. Sheikh ◽  
Li-Qun Fan ◽  
Harini Kandadi ◽  
T. Craig Meagher ◽  
...  
Keyword(s):  
Immune Response ◽  
Clinical Outcome ◽  
Humoral Immune Response ◽  
Tumor Antigens ◽  
Humoral Immune
Sign in / Sign up

Export Citation Format

Share Document